Declining price and increased availability reshape patient access patterns and purchasing behavior, directly influencing who uses cannabis, how much they use, and what forms they choose. Clinicians need to understand these market forces to counsel patients effectively on cost-benefit decisions and risk mitigation.
Market analysis indicates cannabis prices have declined and product availability has expanded, likely driven by legalization in multiple jurisdictions, supply chain maturation, and competition. Lower cost may increase initiation rates and frequency of use among price-sensitive populations, including adolescents and those with limited income. This mirrors public health patterns seen with alcohol and tobacco, where price elasticity significantly influences consumption rates and associated harms.
“Lower cost does not equal lower risk. *I remind patients that affordability is a separate question from indication, dosing, and monitoring. A cheaper product is still cannabis—and the clinical calculus around respiratory risk, dependence liability, and impaired driving remains unchanged.*”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
